Molecular docking and dynamics analysis of selected phytocompounds against multi-targeted hepatocellular carcinoma
Drug Target Insights · 23.04.2026 · 20 (1) · 3-11
DOI: 10.33393/dti.2026.3739 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Target Insights, online erschienen am 23.04.2026. Verfasst von Narendran Chiterasu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Molecular and Nanomedical Science, Sathyabama Institute of Science and Technology, Chennai (Tamil Nadu) - India. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related deaths worldwide, with a five-year survival rate of only 19%. Although Sorafenib is the primary systemic therapy, its limited efficacy and complex interactions with signaling pathways highlight the need for multi-target drugs.
Methods
This study evaluates the anti-cancer properties of selected phytochemicals against six key HCC target proteins, utilizing sorafenib tosylate as a positive control. Molecular docking was performed to evaluate binding affinities and interactions, and ADME/T predictions were generated to estimate drug-like properties. The topranking candidates were further evaluated using 100-ns molecular dynamics simulations to analyze conformational stability, protein-ligand interactions, and residue mobility.
Results
Silymarin (SA) emerged as the most effective compound, demonstrating greater predicted inhibitory activity than Sorafenib. SA showed high binding affinity for target proteins 6HH1 (−9.9 kcal/mol) and 1CM8 (−9.6 kcal/mol). Molecular dynamics simulations also revealed increased stability of the SA-protein complexes, particularly for the 1CM8-SA complex, which maintained high conformational stability. The root-mean-square deviation (RMSD) value was found to be around 2.1 Å, and the root-mean-square fluctuation (RMSF) values werebelow 3 Å, indicating lower protein flexibility compared to both the native and sorafenib-bound complexes.
Conclusion
These computational findings provide a strong theoretical basis for Silymarin’s efficacy as a highly potent, multi-targeted therapeutic agent against HCC. The improved stability and binding properties of Silymarin compared with Sorafenib provide a strong rationale for advancing this compound into preclinical and clinical studies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Centre for Molecular and Nanomedical Science, Sathyabama Institute of Science and Technology, Chennai (Tamil Nadu) - India.
- Rajalakshmi Engineering College, Thandalam, Chennai (Tamil Nadu) - India.
- Department of Gunapadam, National Institute of Siddha, Chennai (Tamil Nadu) - India.
- Centre for Climate Change Studies, International Research Centre, Sathyabama Institute of Science and Technology, Chennai (Tamil Nadu) - India.
- Department of Biotechnology, Sathyabama Institute of Science and Technology, Chennai (Tamil Nadu) - India.
Zitieren
APA
Chiterasu, N., Yanamandala, S., Chinnaiyan, S., Shanthirappan, S., Kannan, S., Clinton, P. X., Vadivel, K., Rangan, K. A., & Yashwanth, S. B. (2026). Molecular docking and dynamics analysis of selected phytocompounds against multi-targeted hepatocellular carcinoma. Drug Target Insights, 20(1), 3-11. https://doi.org/10.33393/dti.2026.3739
Vancouver
Chiterasu N, Yanamandala S, Chinnaiyan S, Shanthirappan S, Kannan S, Clinton PX, et al. Molecular docking and dynamics analysis of selected phytocompounds against multi-targeted hepatocellular carcinoma. Drug Target Insights. 2026;20(1):3-11. doi:10.33393/dti.2026.3739
BibTeX
@article{Chiterasu2026,
author = {Chiterasu, Narendran and Yanamandala, Swarnalatha and Chinnaiyan, Senthilkumar and Shanthirappan, Sivakumar and Kannan, Sidhika and Clinton, Paul X and Vadivel, Karthick and Rangan, Kiruthika Alepalli and Yashwanth, Suresh Babu},
title = {Molecular docking and dynamics analysis of selected phytocompounds against multi-targeted hepatocellular carcinoma},
journal = {Drug Target Insights},
year = {2026},
volume = {20},
number = {1},
pages = {3--11},
doi = {10.33393/dti.2026.3739}
}
EUVIMED